Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Tavaborole
Drug ID BADD_D02119
Description Tavaborale is a novel, boron-based topical antifungal medication for the treatment of onychomycosis, a fungal infection of the nail and nail bed due to *Trichophyton rubrum* or *Trichophyton mentagrophytes* infection. Tavaborole functions by inhibiting Leucyl-tRNA synthetase, or LeuRS, an essential fungal enzyme required for protein synthesis and for the catalysis of ATP-dependent ligation of L-leucine to tRNA(Leu).
Indications and Usage Indicated for the treatment of onychomycosis (a fungal infection) of the toenails due to Trichophyton rubrum or Trichophyton mentagrophytes.
Marketing Status approved; investigational
ATC Code D01AE24
DrugBank ID DB09041
KEGG ID D10169
MeSH ID C512998
PubChem ID 11499245
TTD Drug ID D05VGL
NDC Product Code 69575-4018; 68180-958; 10337-905; 69097-686; 72578-102; 62332-467; 69037-0034; 63629-8704; 69238-1657; 50909-1702; 69766-037; 58175-0614; 66039-932; 51862-690; 70771-1826; 0574-0157; 51672-1397
UNII K124A4EUQ3
Synonyms tavaborole | 5-fluoro-1,3-dihydro-1-hydroxy-2,1-benzoxaborole | AN 2690 | AN2690 | AN-2690 | Kerydin
Chemical Information
Molecular Formula C7H6BFO2
CAS Registry Number 174671-46-6
SMILES B1(C2=C(CO1)C=C(C=C2)F)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Application site dermatitis23.03.04.014; 12.07.01.018; 08.02.01.018--Not Available
Application site erythema23.03.06.005; 12.07.01.001; 08.02.01.0010.002340%Not Available
Application site irritation12.07.01.003; 08.02.01.0030.001671%Not Available
Application site pain12.07.01.004; 08.02.01.0040.003008%Not Available
Application site pruritus08.02.01.005; 23.03.12.004; 12.07.01.0050.001337%Not Available
Application site rash23.03.13.008; 12.07.01.016; 08.02.01.016--Not Available
Blister23.03.01.001; 12.01.06.0020.001003%Not Available
Burning sensation08.01.09.029; 17.02.06.0010.001337%Not Available
Drug ineffective08.06.01.0060.003343%Not Available
Dry skin23.03.03.0010.000669%
Erythema23.03.06.0010.002674%Not Available
Hypersensitivity10.01.03.0030.002006%
Ingrowing nail23.02.05.0110.000669%Not Available
Nail discolouration23.02.05.0010.002104%
Nail disorder23.02.05.0020.000669%
Pain in extremity15.03.04.0100.000669%
Paraesthesia23.03.03.094; 17.02.06.0050.000669%
Paronychia23.11.04.006; 11.02.01.054--
Pruritus23.03.12.0010.001337%
Rash23.03.13.0010.001003%Not Available
Skin exfoliation23.03.07.0030.001671%Not Available
Skin fissures23.03.03.0080.000669%Not Available
Skin irritation23.03.04.0090.003008%Not Available
Urticaria23.04.02.001; 10.01.06.0010.000669%
Application site dryness23.03.03.024; 12.07.01.011; 08.02.01.0110.001337%Not Available
Application site inflammation12.07.01.024; 08.02.01.0240.000669%Not Available
Onychomadesis23.02.05.0060.000669%
Application site exfoliation12.07.01.022; 08.02.01.022; 23.03.07.0070.001671%Not Available
Therapeutic product effect incomplete08.06.01.0520.000669%Not Available
The 1th Page    1    Total 1 Pages